Differentiating the dementias. Revisiting synucleinopathies and tauopathies

Current Alzheimer Research

Volumn 5, Issue 1, 2008, Pages 52-60

  Hickey, Catherine ^a   Chisholm, Terry ^a   Passmore, Michael J ^a   O'Brien, Jonathon Darcy ^a   Johnston, Jennifer ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; BRAIN DYSFUNCTION; CLINICAL FEATURE; COGNITIVE DEFECT; CORTICOBASAL DEGENERATION; DEGENERATIVE DISEASE; DEMENTIA; DEMENTIA WITH LEWY BODY; DISEASE CLASSIFICATION; FRONTOTEMPORAL DEMENTIA; HUMAN; MULTIINFARCT DEMENTIA; PARKINSON DISEASE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; REVIEW; SHY DRAGER SYNDROME; SYNUCLEINOPATHY; TAUOPATHY;

DEMENTIA; DIAGNOSIS, DIFFERENTIAL; HUMANS; PARKINSON DISEASE; SYNUCLEINS; TAU PROTEINS; TAUOPATHIES;

EID: 42149118368     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720508783884657     Document Type: Review

References (84)

1. Ritchie K and Lovestone S. The dementias. The Lancet 360: 1759-1766 (2002).
2. Hofman A, Rocca WA and Brayne C. The prevalence of dementia in Europe: a collaborative study of 1980-1990 findings. Int J Epidemiol 20: 736-748 (1991).
3. Jorm AF, Korten AE and Henderson AS. The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr Scand 76: 465-479 (1987).
4. Ritchie K and Kildea D. Is senile dementia age-related or ageing related? evidence from a meta-analysis of dementia prevalence in the oldest old. The Lancet 346: 931-934 (1995)
5. Barclay LL, et al. Survival in Alzheimer's disease and vascular dementias. Neurology 35: 834-840 (1985).
6. O'Brien JT, Erkinjuntti T and Reisberg B, et al. Vascular cognitive impairment. Lancet Neurol 2: 89-98 (2003).
7. Darvesh S and Freedman M. Subcortical Dementia: A Neurobehavioral Approach. Brain and Cognition (31): 230-249(1996).
8. Albert ML, FEldman RG, Willis AL. The "subcortical dementia" of progressive supranuclear palsy. J Neurol Neurosci Psychiatry 37: 121-130 (1974).
9. Turner MA, Moran NF and Kopelman MD. Subcortical dementia. British Journal of Psychiatry 180: 148-151 (2002).
10. Chan DKY, Parkinson disease and its differentials. Australian Family Physician 30(11): 1053-1056 (2001).
11. McKeith I, et al. Dementia with Lewy bodies. Lancet Neurol 3: 19-28 (2004).
12. Galpern WR, LA, Interface between Tauopathies and Synucleinopathies: A Tale of Two Proteins. Ann Neurol 59: 449-458 (2006).
13. Lippa CF, FH., Mann DM, et al. Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol 153: 1365-1370 (1998).
14. Galvin JE, VM, Lee Y and Trojanowski JQ. Synucleinopathies. Arch Neurol 58: 186-190 (2001).
15. Spillantini MG, SM, Lee VM, et al. Alpha-synculein in Lewy Bodies. Nature 388: 839-840 (1997).
16. Tu PH, GJ, Baba M, et al. Glial cytoplamic inclusions in white matter oligodendrocytes if multiple system atrophy brains contain insoluble alpha-synuclein. Ann Neurol 44: 415-422 (1998).
17. Marsh L, Neuropsychiatric Aspects of Parkinson's Disease. Psychosomatics. 41(1): 15-23 (2000).
18. Mayuex R, Denaro J, Hemenigildo N, et al. A population based investigation of Parkinson's disease with and without dementia: relationships to age and gender. Arch Neurol 49: 492-497 (1992).
19. Emre M. Dementia associated with Parkinson's Disease. Lancet Neurology 2: 229-237 (2003).
20. McKeith IEA. Diagnosis and management of dementia with Lewy bodies, Third report of the DLB consortium. Neurology 65: 1863-1872 (2006).
21. Molloy S, O'BrienJT MI, Burn D. The role of levodopa in the management of dementia in Parkinson disease. Lancet Neurol 76: 1200-1203 (2005).
22. Parkinson J. An Essay on the Shaking Palsy. 1817, London: Whittingham & Rowland.
23. Barbeau A. Parkinson's disease: clinical features and etiopathology. Extrapyramidal Disorders. Handbook of Clinical Neurology. Vol. 49. 1996, Amsterdam: Elsevier Science Publishers. 87-152.
24. Rajput AH. Clinical features and natural history of Parkinson's disease (Special Consideration of Aging). Neurodegenerative Diseases. Philadelphia: W.B. Saunders Company. 555-571 (1996).
25. Aasland D. J Geriatric Psychiatry Neuro 17: 164-171 (2004).
26. Mayeux R, et al. Depression, intellectual impairment, and Parkinson disease. Neurology 31: 645-650 (1981).
27. Gonera EG, van't Hof M and Berger JC, et al. Symptoms and duration of the prodromal phase in Parkinson's disease. Mov Disord 12: 871-876 (1997).
28. Kosaka K. Lewy bodies in cerebral cortex: report of three cases. Acta Neuropathol 42: 127-134 (1978).
29. Giasson BI, Lee VM-Y, Trojanowski JQ, The cellular and molecular pathology of Parkinson' disease, in Neurodegenerative Dementias: Clinical Features and Pathological Mechanisms McGraw-Hill Co: New York. 219-228 (2000).
30. Salmon DP, Galasko D and Hansen LA, et al. Neuropsychological deficits associated with diffuse Lewy body disease. Brain and Cognition 31: 148-165 (1996).
31. McKeith IG. Dementia with Lewy bodies. British Journal of Psychiatry 180: 144-147 (2002).
32. Boeve BF, Silber MH and Ferman TK, et al. REM sleep disorder and degenerative dementia: An association likely reflecting Lewy body disease. Neurology 52: 363-370 (1998).
33. McKeith IG, Perry RH and Fairbairn AF, et al. Operational criteria for senile dementia of Lewy body type (SDLT). Psychological Medicine 22: 911-922 (1992).
34. Louis ED, Klata LA and Lui Y, et al. Comparison of extrapyramidal features in 31 pathologically confirmed cases of diffuse Lewy body disease and 34 pathologically confirmed cases of Parkinson's disease. Neurology 48: 376-380 (1997).
35. Perry EK, McKeith IG and Thompson P, et al. Topography, extent, and clinical relevance of neurochemical deficits in dementia of Lewy body type, Parkinson's disease and Alzheimer's disease. Ann NY Acad Sci 640: 197-202 (1991).
36. Wesnes K, et al. Predicting response to rivastigmine in dementia with Lewy bodies. Eur Neuropsychopharmacol 2002: S373 (2002).
37. Rehman HU.Multiple system atrophy. Postgrad Med J 77: 379-382 (2001).
38. Wenning GK, Ben-Shlomo Y and Magalhaes M, et al. Clinicopathological study of 35 cases of multiple system atrophy. J. Neurol Neurosurg Psychiatry 58: 160-166 (1995).
39. Dejeine J, TA. L'Atrophie olivo-ponto-cerebelleuse. Noveau Inconog. Salpetriere 13: 330-370 (1900).
40. Shy G, DG. A neurologic syndrome with orthostatic hypotension. Arch Neurol 2: 511-527 (1960).
41. Adams R, VanderEeken VL, H, Striato-nigral degeneration. J Neuropathol Exp Neurol 23: 584-608 (1964).
42. Gilman S, Low P and Quinn N, et al. Consensus on the diagnosis of MSA. J Neurol Sci 163: 94-98 (1999).
43. Gilman S, Low PA and Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. J Auton Nerv Syst 74: 189-192 (1998).
44. Wenning GK, Ben-Shlomo Y, and Magalhaes M, et al. Clinical features and natural history of multiple system atrophy: an analysis of 100 cases. Brain 117: 835-845 (1994).
45. Wenning GK, et al. Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord 12: 133-147 (1997).
46. Robbins TW, James M and Lange KW, et al. Cognitive performance in multiple system atrophy. Brain 115: 271-291 (1992).
47. Darvesh S. Multiple System Atophy, in The Encylopedia of Aging, M. GL, Editor. Springer Publishing Company: New York. 962-965 (2001).
48. Wenning GK and Geser F. Multiple System Atrophy. Rev Neurol 159: 3S31-3S38 (2003).
49. Facca AG and Koller WC, Differential Diagnosis of Parkinsonism. Parkinson's Disease: Adv Neurol 91: 383-396 (2003).
50. McKhann G, DD, Folstein M, Katzman R, Price D, Stadlan E. Clinical Diagnosis of Alzheimer's Disease: a report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-944 (1984).
51. Chen P, RG, Belle S, Cauley J, DeKosky S, Ganguli M. Cognitive tests that best discrimminate between presymptomatic AD and those who remain nondemented. Neurology 55: 1847-1853 (2000).
52. Mendez M, CP, Doss D, Argello R, Frey W. Seizures in Alzheimer's Disease: clinicopathologic study. J Geriatr Psychiatry Neurol 7: 230-233 (1994).
53. Mega M, C.J., Fiorello T, Gornbein J, The spectrum of behavioral changes in Alzheimer's Disease. Neurology 46: 130-135 (1996).
54. Mendez MF, CJ. Dementia: significance, definition and epidemiology., in Dementia: A clinical approach. Butterworth Heinemann: Philadelphia. 7-9 (2003).
55. Wragg R, JD., Overview of depression and psychosis in Alzheimer's Disease. Am J Psychiatry 146: 577-587(1989).
56. Pick A. Uber die Beziehungen der senilen Hirnantropie sur aphasie. Prager Medizinshe Wochenscrif 17: 165-167 (1892).
57. TLaM G. Clinical and neuropathological criteria for frontotemporal dementia. J Neuro Neurosurg Psychiatry 57: 416-418 (1994).
58. Neary D, SJ, Mann D. Frontotemporal Dementia. The Lancet 4: 771-789 (2005).
59. Hayward New Frontotemporal-dementia gene identified. Lancet Neurol 5(9): 728 (2006).
60. Neary D, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria [comment]. Neurology 51(6): 1546-54 (1998).
61. Rahman S, S.B., Hodges J, Specific cognitive deficits in mild frontal variant frontotemporal dementia. Brain and Cognition 122: 1469-1493 (1999).
62. Stuss D, JG, Alexander M, The frontal lobes are necessary for "theory of mind". Brain 124: 279-286 (2001).
63. Burn D and Lees AJ, Progressive supranuclear palsy: where are we now. Lancet Neurol 1: 359-369 (2002).
64. Chiasson G and Dugas M Parkinsonian Syndromes. The Canadian J CME, 37-48 (2002).
65. Golbe LI, Davis PH and Schoenberg BS, et al. Prevalence and natural history of progressive supranuclear palsy. Neurology 38: 1031-1034 (1988).
66. Agid Y, Javoy-Agid F and Ruberg M, et al. Progressive supranuclear palsy: anatomoclinical and biochemical considerations. Adv Neurol 45: 191-206 (1987).
67. Litvan I, et al. Memory impairment in patients with progressive supranuclear palsy. Arch Neurol 46: 765-767 (1989).
68. Maher ER, Smith EM and Lees AJ. Cognitive deficits in the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). J Neurol Neurosurg Psychiatry 48: 1234-1239 (1985).
69. Pfaffenbach DD, Layton DD and Kearns T Ocular manifestations in progressive supranuclear palsy. Am J Opthalmol 74: 1179-1184 (1972).
70. Hobson DE. Clinical Manifestations of Parkinson's Disease and Parkinsonism. Can J Neurol Sci 30(1): S2-S9 (2003).
71. Barr A. Progressive supranuclear palsy. In: Vinken, Bruyn, Klawans (Eds) Extrapyramidal Disorders, Vol 49, Handbook of Clinical Neurology 239-254 (1996).
72. Jackson JA, Jankovic J and Ford J. Progressive supranuclear palsy: clinical features and response to treatment in 16 patients. Ann Neurol 13: 273-278 (1983).
73. Masucci EF and Kurtzke JF. Tremor in progressive supranuclear palsy. Acta Neurol Scand 80: 296-300 (1989).
74. Pahwa R. Parkinson's disease and parkinsonian syndromes; progressive supranuclear palsy. Med Clin N Am 83(2): 367-369 (1999).
75. Kumar R, Bergeron C and Pollanen MS, et al. Cortical basal ganglionic degeneration. In: Jankovic J, Tolosa E, eds. Parkinson's disease and movement disorders. Williams & Wilkins, 297-316 (1998).
76. Grimes DA, Lang AE and ergeron CB. Dementia as the most common presentation of cortical-basal ganglionic degeneration. Neurology 53: 1969-1974 (1999).
77. Feany MB, Mattiace LA and Dickson DW. Neuropathologic overlap of progressive supranuclear palsy, Pick's disease, and corticobasal ganglionic degeneration. J Neuropathol Exp Neurol 55: 53-67 (1996).
78. Frattali CM, Grafman J and Patronas N, et al. Language disturbances in corticobasal degeneration. Neurology 54: 990-992 (2000).
79. Quinlan RA, and Nicholl ID. Chaperone activity of alpha crystalline modulates intermediate filament assembly. EMBOJ 13: 948-953 (1994).
80. Ribeiz JJ, Kolodny EH, and Richardson E Corticodentatonigral degeneration with neuronal achromasia. Arch Neurol 18: 20-33 (1968).
81. Mark MH. Movement Disorders. Neurologic Clinics 19(3): 1-18 (2001).
82. Rinne JO, Lee MS and Thompson PD, et al. Corticobasal degeneration: a clinical study of 36 cases. Brain 117: 1183-1196 (1994).
83. Thompson PD, Day BL, and Rothwell JC, et al. The myoclonus in corticobasal degeneration: Evidence for two forms of cortical reflex myoclonus. Brain 117: 1197-1207 (1994).
84. Riley D and Lang A. Corticobasal degeneration, clinical diagnostic criteria. Adv Neurol 82: 29-34 (2000).